uploads/2017/12/Mednax-Analysts-Reco-1.png

The Latest Wall Street Recommendations for Mednax

By

Updated

 

Analysts’ ratings for Mednax

Of the total 14 analysts covering Mednax (MD) in December 2017, three analysts have given the stock a “buy” or higher rating and ten have given it a “hold” rating while one analyst has given it a “sell” rating. The mean rating for the stock is 2.71 with a mean target price of $48.18.

Notably, Mednax makes up about 0.26% of the iShares Core S&P Mid-Cap ETF’s (IJH) total portfolio holdings.

Peer ratings

Of the 20 analysts covering Lifepoint Health (LPNT) in December 2017, five analysts have given the stock a “buy” or higher rating and two analysts have given it a “sell” or lower rating. For Acadia Healthcare Company (ACHC), of the 17 analysts covering the company, ten have given the stock a “buy” or higher rating. Meanwhile, of the 15 analysts covering Envision Healthcare (EVHC), 11 have given it a “buy” or higher rating and five analysts have given it a “hold” rating.

In the next part of this series, we take a look at Mednax’s business strategy.

More From Market Realist